Nearly 7 million Americans have been diagnosed with dementia, which slowly erodes memory, thinking skills and the ability to ...

As the second oral therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer’s disease during the past decade, ZUNVEYL demonstrates a potentially better safety ...

Tens of millions of pounds in investment is being provided by the group of firms which includes AstraZenecaa and Pfizer ...

Effectively treating and preventing this common form of dementia will require a cocktail of drugs and a combination of ...

For decades, scientists have been trying to develop therapeutics for people living with Alzheimer’s disease, a progressive ...

Medical advances make pills to treat Alzheimer’s disease viable, though challenges remain in sharing gains globally ...

A simple digital health tool developed by Australian researchers could soon help predict the age of onset for early Alzheimer ...

A study from the Keck School of Medicine of USC has tested a biomarker linked to vascular dementia across four separate ...

Alpha Cognition and China Medical System sign a $44M licensing deal for Zunveyl. ALPHA-1062 preclinical data shows benefits ...

Summary: A new study has identified a biomarker, DTI-ALPS, which connects glymphatic system dysfunction to vascular dementia.

But that doesn't mean they have to come off the drugs. As with all pills, it's about weighing the pros and cons. Quite aside from the dementia worries, if a patient has been on the tablets for ...